Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Paul Hudson

CEOPaul Hudson

Employees

84,587

Employees84,587

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

84,587

Employees84,587

SNY Key Statistics

Market cap

119.08B

Market cap119.08B

Price-Earnings ratio

12.24

Price-Earnings ratio12.24

Dividend yield

3.25%

Dividend yield3.25%

Average volume

2.95M

Average volume2.95M

High today

$49.16

High today$49.16

Low today

$48.51

Low today$48.51

Open price

$48.54

Open price$48.54

Volume

1.48M

Volume1.48M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

TipRanks 7h

Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 1d

Sanofi’s New COPD Treatment Study: A Potential Game-Changer?

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

Simply Wall St 2d

How Investors Are Reacting To Revvity and Sanofi's Collaboration on Early Type 1 Diabetes Detection

On October 2, 2025, Sanofi announced a collaboration supporting Revvity in expanding its type 1 diabetes (T1D) offering with the development of a new 4-plex in...

More SNY News

Simply Wall St 4d

Novavax Is Down 11.9% After Sanofi Takes Over EU Marketing of Nuvaxovid Vaccine

Sanofi announced it has completed the transfer of European Union marketing authorization for Novavax's COVID-19 vaccine, Nuvaxovid, taking on full commercial an...